Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 173 citing articles:

Natural killer cells in antitumour adoptive cell immunotherapy
Tamara Laskowski, Alexander Biederstädt, Katayoun Rezvani
Nature reviews. Cancer (2022) Vol. 22, Iss. 10, pp. 557-575
Open Access | Times Cited: 489
Roles of natural killer cells in immunity to cancer, and applications to immunotherapy
Natalie K. Wolf, Djem Kissiov, David H. Raulet
Nature reviews. Immunology (2022) Vol. 23, Iss. 2, pp. 90-105
Closed Access | Times Cited: 316
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
David Marín, Ye Li, Rafet Başar, et al.
Nature Medicine (2024) Vol. 30, Iss. 3, pp. 772-784
Open Access | Times Cited: 175
CAR-NK cells for cancer immunotherapy: from bench to bedside
Leisheng Zhang, Meng Yuan, Xiaoming Feng, et al.
Biomarker Research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 134
Innate lymphoid cells and cancer
Nicolas Jacquelot, Cyril Seillet, Éric Vivier, et al.
Nature Immunology (2022) Vol. 23, Iss. 3, pp. 371-379
Open Access | Times Cited: 124
Natural killer cells: a promising immunotherapy for cancer
Junfeng Chu, Fengcai Gao, Meimei Yan, et al.
Journal of Translational Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 114
Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8
Thomas Walle, Joscha A. Kraske, Boyu Liao, et al.
Science Advances (2022) Vol. 8, Iss. 12
Open Access | Times Cited: 99
Emerging Targeted Therapies for HER2-Positive Breast Cancer
María F. Mercogliano, Sofía Bruni, Florencia Mauro, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 1987-1987
Open Access | Times Cited: 82
The changing role of natural killer cells in cancer metastasis
Isaac S. Chan, Andrew J. Ewald
Journal of Clinical Investigation (2022) Vol. 132, Iss. 6
Open Access | Times Cited: 72
Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123
Laurent Gauthier, Angéla Virone-Oddos, Jochen Beninga, et al.
Nature Biotechnology (2023) Vol. 41, Iss. 9, pp. 1296-1306
Open Access | Times Cited: 65
Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering
Li Li, Vakul Mohanty, Jinzhuang Dou, et al.
Science Advances (2023) Vol. 9, Iss. 30
Open Access | Times Cited: 59
The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy
Yanlin Yu
Cancers (2023) Vol. 15, Iss. 8, pp. 2323-2323
Open Access | Times Cited: 55
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment
Roel Polak, Elisa Zhang, Calvin J. Kuo
Nature reviews. Cancer (2024) Vol. 24, Iss. 8, pp. 523-539
Closed Access | Times Cited: 54
Current and future immunotherapeutic approaches in pancreatic cancer treatment
Pooya Farhangnia, Hossein Khorramdelazad, Hamid Nickho, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 38
Evolution of cell therapy for renal cell carcinoma
Yufei Wang, Eloah Rabello Suarez, Gabriella Kastrunes, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 34
IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts
Astrid Van den Eynde, Laura Gehrcken, Tias Verhezen, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 28
Programmable synthetic receptors: the next-generation of cell and gene therapies
Fei Teng, Tongtong Cui, Li Zhou, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 21
Leveraging NKG2D Ligands in Immuno-Oncology
Mercedes B. Fuertes, Carolina I. Domaica, Norberto W. Zwirner
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 95
From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
Hui Lü, Xiaoyan Zhao, Ziying Li, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 89
Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy
Cai Zhang, Yuan Hu, Weihua Xiao, et al.
Cellular and Molecular Immunology (2021) Vol. 18, Iss. 9, pp. 2083-2100
Open Access | Times Cited: 70
Antibody-based cancer therapy
Rebecca S. Goydel, Christoph Rader
Oncogene (2021) Vol. 40, Iss. 21, pp. 3655-3664
Open Access | Times Cited: 68
Engineering the next generation of CAR-NK immunotherapies
Alexander Biederstädt, Katayoun Rezvani
International Journal of Hematology (2021) Vol. 114, Iss. 5, pp. 554-571
Open Access | Times Cited: 66
piggyBac system to co-express NKG2D CAR and IL-15 to augment the in vivo persistence and anti-AML activity of human peripheral blood NK cells
Zhicheng Du, Yu Yang Ng, Shijun Zha, et al.
Molecular Therapy — Methods & Clinical Development (2021) Vol. 23, pp. 582-596
Open Access | Times Cited: 59
The EBMT/EHA CAR-T Cell Handbook
Nicolaus Kröger, John G. Gribben, Christian Chabannon, et al.
Springer eBooks (2022)
Closed Access | Times Cited: 58
STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer
Yanyan Da, Yuxia Liu, Yuan Hu, et al.
OncoImmunology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 57
Page 1 - Next Page

Scroll to top